Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: SRSF7

Summary for SRSF7

Gene information	Gene symbol	SRSF7
	Ensembl ID	ENSG00000115875
	Entrez ID	6432
	Gene name	serine and arginine rich splicing factor 7
	Synonyms	9G8\|AAG3\|HSSG1\|RBM37\|SFRS7\|ZCCHC20\|ZCRB2
	Gene type	protein_coding
	UniProtAcc	Q16629

Top

Dataset with differentially expressed gene: SRSF7

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE138267	CDX	Tumor tissue	Lung cancer	Small cell lung cancer (SCLC)	Chemotherapy	NA	NA	Malignant cells	0.26189	0.00e+00
GSE131984_Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	NA	Malignant cells	0.308252	4.43e-17
GSE163836	FCIBC02 cell line	Cell line	Breast cancer	Inflammatory breast cancer	Chemotherapy	paclitaxel	NA	Malignant cells	-0.471344	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD4+ T cells	0.419785	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	B cells	0.353116	4.30e-05
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.361589	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	0.458173	2.18e-41
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.427702	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.3277	6.55e-23
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	0.621264	0.00e+00
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	0.593128	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	0.336226	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	B cells	-0.294948	2.78e-06
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-1.35712	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-1.76583	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	0.32285	1.30e-02
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.292625	3.34e-06
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.605331	1.37e-30
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.84872	0.00e+00
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	-0.680456	0.00e+00
GSE168668	LNCaP cell line	Cell line	Prostate cancer	Prostate cancer	Targeted therapy	enzalutamide	NA	Malignant cells	0.430571	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	-0.32528	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	-0.457008	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	0.644052	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Erythrocytes	-0.393039	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	B cells	-0.903578	4.25e-03
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	NK cells	0.443548	9.49e-07
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	0.321945	1.98e-06
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	CD4+ T cells	-0.453837	5.69e-04
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	CD8+ T cells	-0.409252	5.62e-10
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	Malignant cells	-0.44971	0.00e+00
GSE131984_JQ1	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1	NA	Malignant cells	-0.679432	0.00e+00
GSE131984_JQ1Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + paclitaxel	NA	Malignant cells	-0.654023	9.81e-45
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	-1.00855	0.00e+00
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	-0.995064	0.00e+00
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	-0.464379	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Erythrocytes	-0.552789	5.36e-06
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Progenitors	-0.611735	1.54e-02
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	0.345623	2.91e-32
GSE164897_VemCob	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib + combimetinib	NA	Malignant cells	0.707559	0.00e+00
GSE164897_VemTra	A375 cell line	Cell line	Melanoma	B+E2:E57RAFV600E-mutant melanoma	Targeted therapy	vemurafenib + trametinib	NA	Malignant cells	-0.452791	0.00e+00

Top

Expression of SRSF7 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to SRSF7

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating SRSF7

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
SRSF7	hsa-miR-3065-5p	96.8475	NM_001031684
SRSF7	hsa-miR-188-5p	96.6962	NM_001031684
SRSF7	hsa-miR-6866-3p	96.6962	NM_001031684
SRSF7	hsa-miR-30b-5p	95.7308	NM_001031684
SRSF7	hsa-miR-30d-5p	95.7308	NM_001031684
SRSF7	hsa-miR-30e-5p	95.7308	NM_001031684
SRSF7	hsa-miR-30c-5p	95.7308	NM_001031684
SRSF7	hsa-miR-30a-5p	95.7308	NM_001031684
SRSF7	hsa-miR-374c-5p	94.8836	NM_001031684
SRSF7	hsa-miR-655-3p	94.8836	NM_001031684
SRSF7	hsa-miR-374a-5p	93.9444	NM_001031684
SRSF7	hsa-miR-4446-5p	93.6531	NM_001031684
SRSF7	hsa-miR-221-5p	92.8189	NM_001031684
SRSF7	hsa-miR-8073	92.8189	NM_001031684
SRSF7	hsa-miR-489-3p	92.3314	NM_001031684
SRSF7	hsa-miR-374b-5p	91.9333	NM_001031684
SRSF7	hsa-miR-7159-5p	89.5416	NM_001031684
SRSF7	hsa-miR-181b-5p	89.4173	NM_001031684
SRSF7	hsa-miR-181c-5p	89.4173	NM_001031684
SRSF7	hsa-miR-181d-5p	89.4173	NM_001031684
SRSF7	hsa-miR-4262	89.4173	NM_001031684
SRSF7	hsa-miR-181a-5p	89.4173	NM_001031684
SRSF7	hsa-miR-372-5p	89.0336	NM_001031684
SRSF7	hsa-miR-2053	88.2043	NM_001031684
SRSF7	hsa-miR-589-3p	85.9326	NM_001031684
SRSF7	hsa-miR-4492	85.9297	NM_001031684
SRSF7	hsa-miR-1468-3p	85.0805	NM_001031684
SRSF7	hsa-miR-4763-5p	85.0575	NM_001031684
SRSF7	hsa-miR-4474-5p	84.3464	NM_001031684
SRSF7	hsa-miR-3158-5p	84.0915	NM_001031684
SRSF7	hsa-miR-527	84.0265	NM_001031684
SRSF7	hsa-miR-518a-5p	84.0265	NM_001031684
SRSF7	hsa-miR-455-5p	83.2378	NM_001031684
SRSF7	hsa-miR-4495	83.1286	NM_001031684
SRSF7	hsa-miR-543	82.2262	NM_001031684
SRSF7	hsa-miR-5585-3p	81.8674	NM_001031684
SRSF7	hsa-miR-6502-3p	81.7495	NM_001031684
SRSF7	hsa-miR-762	81.413	NM_001031684
SRSF7	hsa-miR-5001-5p	81.413	NM_001031684
SRSF7	hsa-miR-586	81.1666	NM_001031684
SRSF7	hsa-miR-4282	80.9098	NM_001031684
SRSF7	hsa-miR-4498	80.2154	NM_001031684

Page: 1

Top

Motifs and transcription factors (TFs) regulating SRSF7

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
SRSF7	hdpi__ETV4	ETV4 (directAnnotation).
SRSF7	taipale_tf_pairs__GCM1_SPDEF_RTGNKGGCGGAWG_CAP_repr	GCM1; SPDEF (directAnnotation).
SRSF7	dbtfbs__GMEB1_K562_ENCSR928KOR_merged_N1	GMEB1 (directAnnotation).
SRSF7	metacluster_15.2	E2F1; E2F1; E2F1; E2F1; E2F1; E2F3; E2F4; E2F4; E2F4; E2F6; E2F6; E2F6; E2F6; E2F6; E2F6; E2F6; E2F7; TFDP1; TFDP2; ZNF566; ZNF566; ZNF574 (directAnnotation). E2F3; E2F3; E2F4 (inferredBy_Orthology).
SRSF7	metacluster_15.1	E2F4; E2F4; E2F4; E2F4; E2F7; ZFP69B (directAnnotation). E2F4 (inferredBy_Orthology).
SRSF7	transfac_pro__M02090	E2F4 (directAnnotation).
SRSF7	metacluster_3.5	KLF14; KLF15; KLF15; KLF16 (directAnnotation).
SRSF7	homer__GGCGGGAARN_E2F6	E2F6 (directAnnotation).
SRSF7	transfac_pro__M02898	SMAD3 (directAnnotation).
SRSF7	metacluster_135.8	ZNF516; ZNF536 (inferredBy_Orthology).
SRSF7	metacluster_55.3	E2F6; EGR1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; NRF1; ZBTB2; ZSCAN10 (directAnnotation). NFE2L1; NRF1; NRF1; NRF1 (inferredBy_Orthology).
SRSF7	dbtfbs__E2F8_representative_N1	E2F8 (directAnnotation).
SRSF7	taipale_cyt_meth__ZNF385D_NCGTCGCGACGN_eDBD_meth	ZNF385D (directAnnotation).
SRSF7	metacluster_197.2	E2F4; E2F7; E2F7; E2F7; E2F8; E2F8 (directAnnotation).
SRSF7	transfac_pro__M00652	NRF1 (directAnnotation).
SRSF7	transfac_pro__M04866	HDAC2 (directAnnotation).
SRSF7	jaspar__MA1122.1	TFDP1 (directAnnotation).
SRSF7	metacluster_34.3	EGR1; ETS1; SETDB1; SIX5; SIX5; ZNF143; ZNF76 (directAnnotation).
SRSF7	metacluster_34.4	ETS1; ETS1; ETS1; HCFC1; SIX5; SIX5; SIX5; SIX5; SMARCC2; SMARCC2; THAP11; THAP11; ZNF143; ZNF143; ZNF143; ZNF143 (directAnnotation). TBX2; THAP11; THAP11; ZNF143 (inferredBy_Orthology).
SRSF7	hdpi__TP73	TP73 (directAnnotation).
SRSF7	transfac_public__M00024	E2F1 (directAnnotation).
SRSF7	swissregulon__mm__E2f7	E2F7 (inferredBy_Orthology).
SRSF7	transfac_pro__M04862	NRF1 (directAnnotation).
SRSF7	jaspar__MA1708.1	ETV7 (directAnnotation).
SRSF7	metacluster_55.5	ZNF541 (directAnnotation).
SRSF7	cisbp__M02645	ETS1 (directAnnotation).
SRSF7	taipale_tf_pairs__ELF2_NATGCGGAAGTR_HT	ELF2 (directAnnotation).
SRSF7	taipale_tf_pairs__ETV2_RFX5_NCCGGAAGYNNCNTAGCAACS_CAP_repr	ETV2; RFX5 (directAnnotation).
SRSF7	taipale_cyt_meth__JUND_NRTGACGCATN_eDBD_repr	JUND (directAnnotation).
SRSF7	metacluster_10.31	MYC (directAnnotation).
SRSF7	transfac_pro__M06130	ZNF254 (directAnnotation).
SRSF7	transfac_pro__M06104	ZNF16 (directAnnotation).
SRSF7	metacluster_168.14	ZNF33A; ZNF33B; ZNF394; ZNF768 (directAnnotation). ZNF768 (inferredBy_Orthology).
SRSF7	metacluster_10.32	MYC (directAnnotation).
SRSF7	metacluster_31.4	ZFP3 (directAnnotation). ZFP3 (inferredBy_Orthology).
SRSF7	transfac_pro__M05550	SNAPC4 (inferredBy_Orthology).
SRSF7	taipale_tf_pairs__TFAP2C_DLX3_NSCCNNNRGGCANNNNYMATTA_CAP_repr	DLX3; TFAP2C (directAnnotation).
SRSF7	kznf__ZNF614_Imbeault2017_RP_ChIP-seq	ZNF614 (directAnnotation).
SRSF7	metacluster_58.12	BATF; FOSL1; FOSL1 (directAnnotation).
SRSF7	metacluster_141.4	GLIS2 (directAnnotation).
SRSF7	transfac_pro__M05854	ZNF619 (directAnnotation).
SRSF7	tfdimers__MD00280	E2F1; OTX1; OTX2 (directAnnotation).
SRSF7	metacluster_144.9	SP2 (directAnnotation).
SRSF7	hocomoco__HSFY1_HUMAN.H11MO.0.D	HSFY1; HSFY2 (directAnnotation).
SRSF7	transfac_pro__M06325	ZNF585A (directAnnotation).
SRSF7	transfac_pro__M06561	ZNF502 (directAnnotation).
SRSF7	cisbp__M01816	JUN (inferredBy_Orthology).
SRSF7	metacluster_52.5	HSFY1; HSFY1; HSFY1; HSFY2; HSFY2; HSFY2 (directAnnotation).
SRSF7	taipale_tf_pairs__ETV2_ONECUT2_RRTCRATNNNCGGAARYN_CAP_repr	ETV2; ONECUT2 (directAnnotation).
SRSF7	transfac_pro__M06800	ZBTB22 (inferredBy_Orthology).

Page: 1 2 3 4

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."